Toyohashi Municipal Hospital

Toyohashi, Aichi-ken 4418570

2 studies enrolling now · 16 studies all time

What they study most

Acute Myeloid Leukemia, B-cell Malignancies, Chronic Myeloid Leukemia, Leukemia, Mantle Cell Lymphoma; Non-Hodgkin Lymphoma, Multiple Myeloma, Non-Small Cell Lung Cancer (NSCLC), Refractory Diffuse Large B-Cell Lymphoma, Refractory Multiple Myeloma, Relapsed Diffuse Large B-Cell Lymphoma, Relapsed Multiple Myeloma, Relapsed or Refractory Multiple Myeloma

Studies at this site

• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) — Recruiting now
• MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) — Recruiting now
• An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• ABTECT - Maintenance — Running, not enrolling
• A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation — Running, not enrolling
• Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Running, not enrolling
• ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 — Completed
• Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies — Running, not enrolling
• Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. — Completed
• A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma — Completed
• Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) — Completed
• Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis — Completed
• Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients — Completed
• Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 — Completed
• Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma — Completed
• Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML — Completed